Disease, Immune Response and Medical Schools

Study reveals how cancer immunotherapy may cause heart inflammation in some patients

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. This study is a game-changer, paving the way to unearthing the roots of these complications.

Immune Response

Immune Response Medical Schools Clinical Trials Treatment

Revolutionary nanoparticles enable gene-editing in lungs

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.

RNA

RNA Medical Schools Engineering DNA

Researchers decipher how a gut bacterium influences immunity

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. It gets its name from the intestinal mucus it breaks down.

Research

Research Immune Response Medical Schools Disease

Not all neoantigens are created equal

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response. Patients with high numbers of clonal neoantigens show improved disease-free survival.

Bioinformatics

Bioinformatics Immune Response DNA Vaccine

Q&A: How a partnership between physicians and researchers aims to make cancer drugs safer

Broad Institute

NOVEMBER 6, 2024

We don’t have good therapeutic solutions and we often have to stop the antitumor therapy or give large amounts of steroids that will also shut down the very immune response that’s fighting the cancer. Patients can even develop life-threatening organ inflammation after a single dose. How did you go about launching this effort?

Research

Research Immune Response Hospitals Therapies

Laurie Glimcher

Broad Institute

JUNE 14, 2023

She is also director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and provost for medical affairs of Cornell University. Glimcher, M.D.,

Medical Schools

Medical Schools Immune Response Science Hospitals

New “dictionary” of immune responses reveals far more complexity in the immune system than previously thought

Broad Institute

DECEMBER 6, 2023

The immune system can carry out many biological processes, from killing viruses to fighting cancer, thanks in large part to approximately 100 key cell-signaling proteins called cytokines, which instruct immune cells what to do. The reference, called the Immune Dictionary , appears today in Nature.

Immune Response

Immune Response RNA Disease Medical Schools

Advances in the Battle Against Autoimmune Disease

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. Autoimmune diseases affect more than 24 million people in the U.S.

Disease

Disease Clinical Trials Small Molecule Trials

A backpack full of multiple sclerosis therapy

The Pharma Data

APRIL 22, 2023

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and function to progressively decline. million individuals that currently have to live with the disease.

Therapies

Therapies Immune Response Small Molecule Engineering

T-cell receptors offer window to the cell for a new class of cancer therapeutics

Drug Target Review

JANUARY 15, 2024

This produces a great advantage in infectious disease, as it becomes difficult for a virus to adapt and spread from person to person, because each person’s HLA array is genetically distinct. Therefore, therapeutically useful tumour antigens represent a tiny fraction of the genes expressed by a tumour cell.

Engineering

Engineering DNA Virus Immune Response

A surprising new role for a major immune regulator

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations

Regulations Clinical Trials Engineering DNA

Therapeutic Vaccine Is Keeping Melanoma in Remission 4 Years On

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan. SOURCES: Patrick A.

Vaccine

Vaccine Immune Response Medical Schools Clinical Trials

Tiziana Life Sciences plc announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan. NEW YORK and LONDON, Jan.

Clinical Trials

Clinical Trials Science Treatment Trials

AI Tool CHIEF Paints a Landscape of a Cancer, Refining Diagnosis, Treatment, and Prognosis

PLOS: DNA Science

SEPTEMBER 5, 2024

Researchers from Harvard Medical School describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer. Their report appears in Nature.

Treatment

Treatment FDA Approval DNA Small Molecule

Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

The Pharma Data

NOVEMBER 1, 2020

Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. NEW YORK and LONDON, Nov.

Clinical Trials

Clinical Trials Trials Medical Schools Hospitals

Scientists find a region of the mouse gut tightly regulated by the immune system

Broad Institute

NOVEMBER 20, 2024

The intestine maintains a delicate balance in the body, absorbing nutrients and water while maintaining a healthy relationship with the gut microbiome, but this equilibrium is disrupted in parts of the intestine in conditions such as celiac disease, ulcerative colitis, and Crohn’s disease.

Regulations

Regulations Immune Response Molecular Biology Disease

Another COVID-19 Vaccine Candidate Begins Final Clinical Trials

The Pharma Data

DECEMBER 29, 2020

The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. National Institute of Allergy and Infectious Diseases, said last week. “They know someone who had a severe case or died. .

Clinical Trials

Clinical Trials Vaccine Trials Immune Response

Drug Discovery Digest

Study reveals how cancer immunotherapy may cause heart inflammation in some patients

Revolutionary nanoparticles enable gene-editing in lungs

Trending Sources

Researchers decipher how a gut bacterium influences immunity

Not all neoantigens are created equal

Q&A: How a partnership between physicians and researchers aims to make cancer drugs safer

Laurie Glimcher

New “dictionary” of immune responses reveals far more complexity in the immune system than previously thought

Advances in the Battle Against Autoimmune Disease

A backpack full of multiple sclerosis therapy

T-cell receptors offer window to the cell for a new class of cancer therapeutics

A surprising new role for a major immune regulator

Therapeutic Vaccine Is Keeping Melanoma in Remission 4 Years On

Tiziana Life Sciences plc announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil

AI Tool CHIEF Paints a Landscape of a Cancer, Refining Diagnosis, Treatment, and Prognosis

Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Scientists find a region of the mouse gut tightly regulated by the immune system

Another COVID-19 Vaccine Candidate Begins Final Clinical Trials

Stay Connected